drugset / Trial / NCT04356742
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
RandomizedParallel-groupTriple-blindTreatment
Summary
This study evaluates the addition of dapagliflozin in the treatment of type 2 diabetes with metformin and evogliptin combination therapy. Half of subjects will receive dapagliflozin, metformin and evogliptin, while the other half will receive placebo, metformin and evogliptin.
Timeline
- Start
- 2020-05-26
- Primary completion
- 2022-02-23
- Completion
- 2022-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |
| Background | Evogliptin | Small molecule | 5 mg | Oral |
| Background | Metformin | Small molecule | 1000 mg | Oral |